Delisting of Kiadis will be effective on 25 May 2021 - Seite 3

Kiadis Kiadis Pharma N.V. Paasheuvelweg 25A 1105 BP Amsterdam The Netherlands

Settlement Agent ING Bank N.V. Bijlmerdreef 106 1102 CT Amsterdam The Netherlands

For more information:

Kiadis: Maryann Cimino, Sr. Manager, Corporate Affairs Tel: [phone] [e-mail] Kiadis Media Relations Contacts LifeSpring Life Sciences Communication: Leon Melens (Amsterdam) Tel: [phone] [e-mail] Optimum Strategic Communications: Mary Clark, Supriya Mathur Tel: [phone] [e-mail]

Sanofi: Sanofi Media Relations Contact Ashleigh Koss Tel.: [phone] [e-mail] Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco IR main line: Tel.: [phone] [e-mail]

About Kiadis
Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

About Sanofi
Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. Sanofi prevents illness with vaccines and provides innovative treatments to fight pain and ease suffering. Sanofi stands by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life.

Disclaimer
This press release contains inside information within the meaning of the EU Market Abuse Regulation (596/2014).